Pharmacogenetic approaches in the treatment of asthma.
A patient's response to asthma therapy is determined by both genetic and environmental factors. In the past 10 years, we have witnessed significant progress in the field of asthma pharmacogenetics--the study of how a patient's genetic background determines the efficacy and potential for adverse effects to current asthma medication. There are now clear examples of gene polymorphisms that can influence responses to beta(2)-agonists, glucocorticosteroids, and leukotriene modifier drugs, the three main classes of medication used clinically to treat asthma. Identification of genetic polymorphism that predicts drug responses has the potential to lead to the development of new therapeutics, improve asthma management, and reduce serious episodes and hospitalizations. In this review, we discuss the current understanding of asthma pharmacogenetics, focusing on the main three classes of drugs currently used clinically.
Sayers
Ian
I
Division of Therapeutics and Molecular Medicine, University Hospital of Nottingham, D Floor, South Block, Nottingham, NG7 2UH, UK.
Hall
Ian P
IP
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics; D001249:Asthma / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D013806:Theophylline / Q000627:therapeutic use
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D018727:Muscarinic Antagonists; D013806:Theophylline; D001094:Arachidonate 5-Lipoxygenase; D005982:Glutathione Transferase; C041116:leukotriene-C4 synthase